Biomolecules and Biomedicine,
Journal Year:
2023,
Volume and Issue:
unknown
Published: Jan. 15, 2023
Cuproptosis,
a
copper-induced
mechanism
of
mitochondrial-related
cell
death,
has
been
implicated
as
breakthrough
in
the
treatment
cancer
and
become
new
strategy.
Furthermore,
long
non-coding
RNA
(lncRNA)
can
change
biological
activities
tumor
cells.
Worldwide,
lung
squamous
carcinoma
(LUSC)
is
among
most
common
annoying
tumors.
LncRNAs
related
to
cuproptosis
are
not
researched
at
LUSC.
Our
research
intends
develop
signature
on
basis
cuproptosis-associated
lncRNAs,
which
predict
LUSC
prognosis
investigate
immunological
features.
The
TCGA
database
was
used
retrieve
transcriptome,
clinical,
gene
mutation
data.
For
statistical
analysis,
we
utilized
R
program.
We
created
consisting
three
cuproptosis-related
lncRNAs
this
investigation
(including
AC002467.1,
LINC01740,
LINC02345).
Survival
analyses
Receiver
Operating
Characteristic
curves
demonstrated
that
possessed
powerful
predictive
capability.
signature’s
ability
confirmed
by
curve
principal
component
analysis.
Notably,
patient
with
high-risk
score
high
burden
level
had
lower
survival
time.
immune
dysfunction
exclusion
analysis
showed
these
individuals
low-risk
scores
may
benefit
from
immunotherapy.
constructed
be
prognostic
markers
It
contributes
immunotherapy
offers
LUSC’s
therapy
direction.
Advanced Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 23, 2025
Abstract
Cervical
cancer
(CC)
is
a
major
health
threat
to
women,
with
immunotherapies
targeting
the
programmed
death
receptor
1/programmed
ligand
1(PD‐1/PD‐L1)
axis
showing
promise
but
encountering
resistance
in
significant
patient
population.
This
has
driven
critical
quest
uncover
underlying
mechanisms.
study
uncovers
novel
metabolic
involving
nicotinamide
adenine
dinucleotide
(NAD
+
)
salvage
pathway
enzyme
phosphoribosyltransferase
(NAMPT)
and
deacetylase
Sirtuin
1
(SIRT1),
which
regulates
PD‐L1
expression
nuclear
localization
CC.
may
be
key
factor
contributing
observed
immunotherapy.
reveals
that
overexpression
cancers
regulated
by
both
transcriptional
post‐transcriptional
processes.
Acetyl‐proteomic
analysis
pinpoints
SIRT1
as
central
regulator
deacetylation
of
histone
H3
at
lysines
27,
influence
subcellular
distribution.
finding
epigenetic
control
immune
checkpoint
proteins
pathways,
offering
new
perspective
on
regulation
PD‐L1.
The
identification
NAMPT/SIRT1
suggests
this
enhance
therapeutic
responses.
BMC Cancer,
Journal Year:
2025,
Volume and Issue:
25(1)
Published: March 21, 2025
Predicting
the
response
to
neoadjuvant
chemoimmunotherapy
in
patients
with
resectable
non-small
cell
lung
cancer
(NSCLC)
facilitates
clinical
treatment
decisions.
Our
study
aimed
establish
a
machine
learning
model
that
accurately
predicts
pathological
complete
(pCR)
using
18F-FDG
PET
radiomics
features.
We
retrospectively
included
210
NSCLC
who
completed
and
subsequently
underwent
surgery
results,
categorising
them
into
training
set
of
147
test
63
patients.
Radiomic
features
were
extracted
from
primary
tumour
lymph
nodes.
Using
10-fold
cross-validation
least
absolute
shrinkage
selection
operator
method,
we
identified
most
impactful
radiomic
The
screened
univariate
multivariate
analyses.
Machine
models
developed
random
forest
leading
establishment
one
feature
model,
two
fusion
models.
performance
these
was
evaluated
based
on
area
under
curve
(AUC).
In
set,
three
showed
comparable
AUC
values,
ranging
0.901
0.925.
underperformed,
an
0.677.
Fusion_LN1LN2
achieved
highest
(0.823),
closely
followed
by
Fusion_Lnall
0.729.
moderate
0.666,
whereas
had
lowest
at
0.631.
Additionally,
demonstrated
positive
net
reclassification
improvement
integrated
discrimination
values
compared
other
models,
employed
SHapley
Additive
exPlanations
methodology
interpret
results
our
optimal
model.
18F-FDG-PET,
will
assist
clinicians
predicting
pCR
before
for
NSCLC.
Molecular Cancer,
Journal Year:
2025,
Volume and Issue:
24(1)
Published: April 9, 2025
Non-small
cell
lung
cancer
(NSCLC)
represents
the
most
common
pathological
type
of
cancer,
and
combination
neoadjuvant
immunotherapy
with
chemotherapy
has
emerged
as
first-line
treatment
for
NSCLC.
Nevertheless,
efficacy
this
therapeutic
approach
remains
variable.
The
present
study
aims
to
examine
impact
chemoimmunotherapy
in
NSCLC
patients,
a
view
identifying
key
molecules,
critical
subpopulations,
communication
patterns
spatial
distributions
that
potentially
correlate
sensitivity.
A
total
16
tissue
samples
were
collected
from
cohort
12
patients
subjected
single-cell
RNA
transcriptome
sequencing.
Our
data
demonstrated
distribution
CD4
+
Treg
T
cells
mCAFs
indicated
an
immunosuppressive
tumor
microenvironment,
while
accumulation
Th17
iCAFs
could
act
positive
marker
sensitivity
chemoimmunotherapy.
Furthermore,
significant
high
level
SELENOP-macrophages
was
observed
tissues
responders,
strong
co-localization
between
antigen-presenting
associated
fibroblasts
(CAFs)
boundaries
identified,
indicating
cooperative
roles
these
two
types
response
combined
therapy.
Moreover,
be
accumulated
tertiary
lymphoid
structures,
which
further
suggested
its
role
recruiting
lymphocytes.
analysis
cell-cell
communication,
based
on
transcriptomics,
suggests
interactions
SELENOP-macrophages,
apCAFs,
CD8
significantly
enhanced
responders.
In
addition,
recruited
Naïve,
Helper
Naïve
through
pathways
such
cholesterol,
interleukin,
chemokine
HLA
when
responding
unveils
dynamic
transcriptional
changes
microenvironment
non-small
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: April 16, 2025
Introduction
Neoadjuvant
immunochemotherapy
(nICT)
has
significantly
improved
event-free
survival
(EFS)
and
pathologic
complete
response
(pCR)
in
patients
with
resectable
non-small
cell
lung
cancer
(NSCLC).
However,
the
lack
of
validated
biomarkers
limits
their
ability
to
predict
therapeutic
efficacy
outcomes.
This
study
aimed
develop
a
novel
inflammatory
nutritional
index,
Lung
Cancer
Immune
Prognostic
Score
(LCIPS),
pCR
prognosis
NSCLC.
Methods
retrospective
included
131
clinical
stage
IB-IIIB
NSCLC
who
underwent
neoadjuvant
between
May
2020
2024.
Baseline
data
hematological
parameters
were
collected.
Lasso
regression
analysis
was
employed
identify
indices
associated
pCR,
LCIPS
constructed
based
on
these
factors.
Kaplan-Meier
log-rank
tests
used
assess
differences.
Logistic
performed
predictors
while
Cox
determined
independent
prognostic
factors
for
disease-free
(DFS)
overall
(OS).
The
predictive
performance
using
nomogram.
Results
identified
three
core
indices:
albumin-to-globulin
ratio
(A/G),
absolute
monocyte
count
(MONO),
lymphocyte
(LYM).
formula
as
follows:
LCIPS=0.900×A/G+0.761×MONO
(10
9
/L)
−0.065×LYM
/L).
Receiver
operating
characteristic
(ROC)
curve
showed
that
had
superior
(area
under
(AUC)
=
0.68)
compared
other
classical
markers.
Univariate
multivariate
logistic
analyses
intraoperative
lymph
node
dissection
status
A/G
(
p
<
0.05).
Multivariate
demonstrated
smoking
DFS
OS.
Nomogram
validation
indicated
robust
accuracy
LCIPS.
Notably,
among
immune-related
adverse
events
(irAEs),
endocrine-
cardiac-related
irAEs
affected
Discussion
is
an
predictor
receiving
index
offers
valuable
guidance
personalized
treatment
strategies.
Acta Oto-Laryngologica,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 6
Published: April 23, 2025
Uncovering
the
molecular
mechanisms
of
cancer
pathogenesis
is
crucial
for
improving
survival
outcomes.
This
study
investigates
impact
programmed
death
ligand
1
(PD-L1)
expression
on
risk
progression
in
patients
with
oral
squamous
cell
carcinoma
(OSCC).
The
retrospective
included
adult
diagnosed
OSCC
between
January
2012
and
December
2023.
PD-L1
tissue
removed
by
definitive
surgery
was
evaluated
using
immunohistochemistry,
tumor
proportion
score
(TPS)
combined
positive
(CPS)
were
calculated.
Survival
analyses
performed
to
assess
its
prognostic
implications.
Among
96
patients,
TPS
CPS
20%
or
above
52
(54.2%)
65
(67.7%)
cases,
respectively.
≥20%
associated
mucosal
lip
location,
earlier
disease
stage,
decreased
progression.
multivariate
Cox
regression
model
revealed
that
stage
III/IV
(HR:
2.176,
95%CI:
1.085-4.376,
p
=
.029)
0.241,
0.066-0.879,
.031)
independent
factors
progression-free
survival.
increased
tumoral
may
reduce
OSCC.
These
findings
underscore
potential
significance
following
surgical
resection.
Frontiers in Oncology,
Journal Year:
2023,
Volume and Issue:
12
Published: Jan. 24, 2023
Immune
checkpoint
inhibitors
(ICIs)
are
highly
concerned
in
the
treatment
of
non-small
cell
lung
cancer
(NSCLC),
represented
by
programmed
death
protein
1
(PD-1)
and
its
ligand
(PD-L1),
cytotoxic
T
lymphocyte-associated
antigen-4
(CTLA-4).
The
introduction
immunotherapy
perioperative
NSCLC
has
improved
prognosis
to
a
great
extent,
as
demonstrated
several
phase
II
III
clinical
trials.
target
population
for
early-stage
is
still
under
discussion,
biomarkers
neoadjuvant
selection
next
pending
problem.
predictive
efficacy
many
potential
makers
being
explored,
including
PD-L1
expression
levels,
tumor
mutation
burden,
circulating
DNA,
components
microenvironment,
factors.
We
summarize
key
findings
on
utility
ICIs
trials
preoperative
patients
conclude
analyses
relevant
provide
better
understanding
potentially
immunotherapy.
Frontiers in Bioengineering and Biotechnology,
Journal Year:
2023,
Volume and Issue:
11
Published: June 7, 2023
Immune
checkpoint
blockade
is
now
recognized
as
a
paradigm-shifting
cancer
therapeutic
strategy,
whereas
there
remains
difficulty
in
accurately
predicting
immunotherapy
efficacy
by
PD-L1
expression.
In
addition,
radiotherapy
for
patients
faces
the
problem
of
insufficient
dose
at
tumor
site
while
which
have
been
not
tolerated
normal
tissues.
this
study,
we
created
aptamer-anchored
spherical
nucleic
acids
(SNAs)
with
shell
made
aptamer
and
indocyanine
green
(ICG)
embedded
mesoporous
hafnium
oxide
nanoparticle
core
(Hf@ICG-Apt).
Upon
low
pH
irradiation
sites,
nano-system
enabled
release
ICG
high
expression
to
develop
tumor-to-background
ratio
7.97
±
0.76
enhanced
retention
more
than
48
h.
Moreover,
Hf@ICG-Apt
improved
radiation
therapy
(RT)
when
combined
radiation.
Notably,
showed
scarcely
any
systemic
toxicity
vivo
.
Overall,
research
offered
novel
approach
applying
reliable
monitoring
localization
robust
RT
sensitization
against
good
biosafety.
Frontiers in Oncology,
Journal Year:
2023,
Volume and Issue:
13
Published: March 28, 2023
The
relationship
between
cuproptosis
and
HCC
is
still
in
the
exploratory
stage.
Long
noncoding
RNAs
(lncRNAs)
have
recently
been
linked
to
progression
of
hepatocellular
carcinoma
(HCC).
However,
clinical
significance
lncRNAs
associated
with
remains
unclear.Based
on
Cancer
Genome
Atlas
(TCGA)
liver
(LIHC)
dataset,
we
identified
characteristic
prognostic
by
univariate,
LASSO,
multifactorial
regression
analysis,
constructed
a
signature
cuproptosis-related
HCC.
role
were
through
CCK-8,
clone
formation
Huh-7
cells
high
expression
FDX1.
Prognostic
potential
was
evaluated
each
two
cohorts
created
randomly
dividing
TCGA
cohort
into
training
test
1:1
ratio.
Immune
profiles
defined
subgroups
lncRNA
features
as
well
drug
sensitivity
analyzed.We
multigene
based
four
(AL590705.3,
LINC02870,
KDM4A-AS1,
MKLN1-AS).
These
participated
development
cuproptosis.
patients
classified
high-risk
low-risk
groups
median
value
risk
score.
receiver
operating
curve
area
under
values
for
1-,
3-,
5-year
survival
0.773,
0.728,
0.647,
respectively,
cohort,
0.764,
0.671,
0.662,
cohort.
Univariate
analyses
indicated
that
this
feature
an
independent
factor
Principal
component
analysis
plots
clearly
distinguished
low-
terms
their
probability
survival.
Furthermore,
gene
set
enrichment
showed
variety
processes
tumor
proliferation
enriched
group
compared
group.
Moreover,
there
significant
differences
immune
cell
subpopulations,
checkpoint
genes,
screening,
which
provided
distinct
therapeutic
recommendations
individuals
various
risks.We
novel
cuproptosis-associated
predictive
prognosis
Cuproptosis-associated
are
microenvironment
even
efficacy
immunotherapy.
Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: Aug. 3, 2023
The
utilisation
of
neoadjuvant
immunotherapy
has
demonstrated
promising
preliminary
clinical
outcomes
for
early-stage
resectable
non-small-cell
lung
cancer
(NSCLC).
Nevertheless,
it
is
imperative
to
develop
novel
combination
therapy
regimens
incorporating
further
enhance
the
proportion
patients
who
derive
benefit.
Recent
studies
have
revealed
that
stereotactic
body
radiotherapy
(SBRT)
not
only
induces
direct
tumour
cell
death
but
also
stimulates
local
and
systemic
antitumour
immune
responses.
Numerous
trials
incorporated
SBRT
into
advanced
NSCLC,
revealing
this
effectively
inhibits
growth
while
simultaneously
activating
Consequently,
integration
with
emerged
as
a
strategy
treating
can
response
eradicate
micrometastases
recurrent
foci
post-resection.
This
review
aims
elucidate
potential
mechanism
followed
by
surgery
identify
optimal
treatment
strategies.
Initially,
we
delineate
interplay
between
microenvironment,
well
response.
We
subsequently
introduce
preclinical
foundation
combined
NSCLC.
Finally,
discussed
dosage,
schedule,
biomarkers
in
its
application.
In
conclusion,
elucidation
offers
theoretical
basis
ongoing
contributes
determining
most
efficacious
scheme
future